Modeled Survival Gains of Patients with Cystic Fibrosis (CF) Aged ≥12 Years Homozygous for the F508dEL Mutation Treated with the CF Transmembrane Conductance Regulator Modulator (CFTRM) Tezacaftor/Ivacaftor (TEZ/IVA)